{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:14:20Z","timestamp":1786997660726,"version":"build-2736575974"},"reference-count":11,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.transproceed.2017.09.069","type":"journal-article","created":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T22:51:03Z","timestamp":1521586263000},"page":"619-622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and Safety of Anti\u2013TNF-\u03b1 Agents in Inflammatory Bowel Disease After Liver Transplant: A Case Series"],"prefix":"10.1016","volume":"50","author":[{"given":"R.V.","family":"Olmedo-Mart\u00edn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Amo-Trillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Gonz\u00e1lez-Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Tenorio-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"S\u00e1nchez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"de la Cruz-Lombardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Rodrigo-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Jim\u00e9nez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2017.09.069_bib1","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.cgh.2011.08.027","article-title":"Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis","volume":"9","author":"Ngu","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.transproceed.2017.09.069_bib2","doi-asserted-by":"crossref","first-page":"e0135807","DOI":"10.1371\/journal.pone.0135807","article-title":"Solid organ transplantation in patients with inflammatory bowel diseases (IBD): analysis of transplantation outcome and IBD activity in a large single center cohort","volume":"10","author":"Schnitzler","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.transproceed.2017.09.069_bib3","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.3748\/wjg.v23.i18.3214","article-title":"Inflammatory bowel disease in liver transplanted patients","volume":"23","author":"Kanizaj","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.transproceed.2017.09.069_bib4","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2017.09.069_bib5","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/ajg.2010.33","article-title":"Anti-tumor necrosis factor therapy for inflammatory bowel disease in the setting of immunosuppression for solid organ transplantation","volume":"105","author":"El-Nachef","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.transproceed.2017.09.069_bib6","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2036.2012.05217.x","article-title":"Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients","volume":"36","author":"Mohabbat","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.transproceed.2017.09.069_bib7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2036.2012.05141.x","article-title":"The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series","volume":"36","author":"Sandhu","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.transproceed.2017.09.069_bib8","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/apt.12256","article-title":"Letter: infliximab therapy in inflammatory bowel disease patients after liver transplantation","volume":"37","author":"Indriolo","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.transproceed.2017.09.069_bib9","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/lt.24212","article-title":"Antitumor necrosis \u03b1 treatment in primary sclerosing cholangitis associated inflammatory bowel disease after liver transplantation","volume":"21","author":"Pavlidis","year":"2015","journal-title":"Liver Transpl"},{"key":"10.1016\/j.transproceed.2017.09.069_bib10","unstructured":"Westerouen van Meeteren MJ, Hayee B, Inderson A, et\u00a0al. Safety of anti-TNF treatment in liver transplant recipients\u2014a systematic review and meta-analysis. J Crohns Colitis (in press)."},{"key":"10.1016\/j.transproceed.2017.09.069_bib11","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/lt.21260","article-title":"Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation","volume":"14","author":"Cholongitas","year":"2008","journal-title":"Liver Transpl"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134517309399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134517309399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,2]],"date-time":"2018-07-02T16:49:44Z","timestamp":1530550184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134517309399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0041134517309399"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2017.09.069","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Anti\u2013TNF-\u03b1 Agents in Inflammatory Bowel Disease After Liver Transplant: A Case Series","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2017.09.069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}